• Imagine the cure to an Auto-Immune Disease 100
years ago and no one noticed.
In 1922 another pioneer to experiment with
Light Therapy was Kurt Naswitis who directly irradiated the blood
with UV light through a shunt.
During the 1920’s and continuing through the 1930’s the infamous
Seattle scientist Dr. Emmett Knott, Dr. Sc., sought to harness, in
an extracorporeal way, the known bactericidal property of
ultraviolet rays in order to treat infectious diseases of the blood.
On September 11, 1928 Knott received Patent Number 1,683,877 for the
“Means for Treating Bloodstream Infections” as a result of a
application filed on March 3, 1927 for a UV apparatus he built.
Subsequently he received Patent Number 2,308,516 on January 19,
LESTER EDBLOM AND EMMET KNOTT
• Lester Edblom, medical student
and Dr. Emmet Knott scientist, developed the first Hemo-Irradiator,
vacuum extraction system and cuvette.
The first Patent was issued in the USA for a UV-Irradiator.
September 11, 1928.
• Thousands of people were treated between the 1930’s up to 1959
with a 98% success rate
Patent. Figs: 1, 2, 3, 4 and 5
detail the, extraction and dilution process, the Cuvette,
Irradiation Chamber, some Tubing and an Adaptor.
Hemo-Irradiator (Circa 1947)
Original Model used extensively until the late 1950’s. that
contained certain changes to the apparatus. The machine received an
FDA “grandfather” status as a device that was sold and distributed
in interstate commerce prior to 1976.
By the early 1940’s UV blood irradiation was
being used in several American hospitals. Into the middle of the
1940’s, numerous reports were made about the efficacy for infections
and complete safety of UV blood irradiation therapy. With the
emergence of antibiotic therapy, and the billions being pushed on
the medical industry to the Doctors by the pharmaceutical companies,
UBI therapy was suddenly pushed aside for a more profitable form of
A multitude of articles appeared in the
American literature detailing a novel treatment for various
infections and diseases. This treatment had a cure rate of 98% to
100% in early and moderately advanced infections, and approximately
50% in terminally moribund patients. Healing was not limited to just
bacterial infections, but was also viral, ( acute polio ), Lupus,
wounds, asthma, and arthritis.
The “Tulsa World Newspaper” in 1951
describes how Biophotonic Therapy helped in the fight against
Nephritis in children. This particular study demonstrated a success
rate of 97%.
In the ensuing years, Germany literature demonstrated the
effectiveness of UV irradiation in vascular conditions.
Additionally, more thorough observations of significant improvement
in many physiologic processes and parameters have been reported.
German literature has also demonstrated profound improvements in a
number of biochemical and hematological markers.
By the late 1940’s several dozen physicians
were regularly using Knott’s device according to the technique
established by Knott. They treated bacterial infections, pneumonia,
poliomyelitis, botulism, non-healing wounds, encephalitis,
peritonitis, asthma, pelvic inflammatory disease (PID), Biliary
Disease, Hepatitis, and many other infectious, inflammatory, and
Surgeons were particularly interested in the use of UBI pre- and
post-operationally to treat infections. And The American Journal of
Surgery ran many articles on Biophotonic Therapy Pre and Post
Proponents of UBI published their findings in
dozens of scientific articles. Thousands of patients were treated at
leading centers like Georgetown University Hospital. UBI fared well
in several clinical trials with controls.
Caption from preceding Slide Reads:
“NEW YORK INFIRMARY
USES NEW ALLY IN RESEARCH AGAINST RHEUMATIC FEVER"
Research workers find evidence that the Heart recovers more rapidly
from the ravaging effects of Rheumatic Fever when the blood of the
patient is irradiated with Ultraviolet Light. To date, ninety-eight
(98) Children have already been returned to good health by this
Article proving Biophotonic Therapy was
utilized extensively in the U.S. in the 1940’s. This article
describes the beneficial effects of Biophotonic Therapy in 98
children with Rheumatic Fever.
In Europe, Czech physician Karel Havlicek and
others began using UBI via muscular reinjection of small doses,
often just 10 ml. Federico Wehrli treated oxygenated blood with UV
in a procedure termed Hematogenic Oxidation Therapy ( HOT ). Since
then, HOT has enjoyed certain popularity in Central Europe.
The dramatic advances in antibiotic, vaccine,
and corticosteroids in the 1950’s put a halt to the growing interest
in UBI therapy. Amid the enthusiasm over the new wonder drugs, only
a handful of physicians continued to use it. Even though it was
illogical to set aside a therapy that could treat viral diseases (
e.g., chronic hepatitis and viral pneumonia ) that were impervious
to antibiotics, this illogicality came to pass. From 1955 until the
1990’s only a few American Physicians continue to work with UBI
devices. It did, however receive FDA Approval status as a device
that was sold and distributed in interstate commerce prior to 1976.
In Germany practitioners persisted in using
Biophotonic Therapy. By the 1980’s, BT had become popular among East
Germany and Russian physicians. In the 1990’s, Russian physicians
began to use low-intensity lasers to treat the blood through a fiber
inserted into a vein with an IV needle ( LUBI ). Now, concerns over
the side effects of drugs, efforts to control costs and the HIV
epidemic have led medical researchers and physicians to seek to
combat infections and autoimmune diseases with innovative approaches
such as BT.
Dr. Carl Schliecher; Director of the Foundation for Blood
Irradiation received Exclusive Rights to the Knott Hemo-Irradiator
for Canada on February 21, 1997 and for the US on July 20, 1999.
The Exclusive Rights to the Knott Hemo-Irradiator
was sold to the Foundation for Blood irradiation who later sold
those rights to NPC who recently assigned those Exclusive Rights to
UBI Technologies. The Documents have been entered into public record
in the US.
Many others in Europe and America followed the steps of Finsen and
Knott, such as Miley, Christenson, Beck, Olney, Anderson, Hancock,
Rebbeck, Barrett, Moser, Bland, Von Pohle, Woolfan, Hughes, Beroza,
Davidson, Stauffer, Havens, Sborov, Barmasov and Collbert to mention
some notable physicians. These physicians combined, performed over
300,000 clinical tests, and besides their great curative success,
the most notable fact they mention is that not one person died from
this treatment modality throughout 50 years of testing.
William Campbell Douglass, the Author of “Into The Light” is
considered the modern day “Guru” who has had notable gains in recent
years, because his treatment modality was virtually drug free and
Dr. Edelson at Yale University developed a form of Blood Irradiation
termed “Photopheresis”, which entailed triggering chemotherapy with
a small dose of UVBI.
He is also associated with Therakos®, a
subsidiary of Johnson & Johnson, that has a FDA approved
Photopheresis machine. The major drawback of the Therakos® treatment
modality is its prohibitive cost ($5000 per treatment) and long
sessions that last between four to five hours each treating only 1
disease T-Cell Lymphoma.
The Knott Hemo-Irradiator
extensively in the U.S. throughout the last 20 years.
Dr. Kent Gray received his Bachelors and
Masters degrees from Central Michigan University, and his PhD in
Public Health Administration from Indiana University.
Dr. Gray was deemed to be the “most innovative
public health director in the State of Michigan” for his work and
leadership in the control of communicable diseases and in the
promotion of community-based environmental health programs.
During an epidemic of the Swartz Strain of
Measles Dr. Gray discovered a vaccine that immediately saved the
lives of more than 3,000 children and went on to vaccinate an
additional 7,000 children.
Through this experience Dr. Gray developed a
process that is now used all over the world to treat communicable
Later in his career, Dr. Gray formed a company
called National Photoluminescence Center NPC which developed and
build Hemo-Aide. NPC was also able to obtain the Exclusive Rights to
the Patent and Trademark for the Knott Hemo-Irradiator on January
Douglas Sielaff, Founder and CEO of UBI
Technologies, now has Exclusive Rights to all Patents and Trademarks
for the Hemo-Aide, the Q-vet, and the Knott Hemo-Irradiator.
The Lineal descent of the Knott Hemo-Irradiator,
The Hemo-Aide TM